Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects.

Zhongguo yao li xue bao = Acta pharmacologica Sinica - 1 Aug 1999

Cai W M, Chen B, Cai M H, Zhang Y D

Abstract excerpt

AIM: To determine the role of the CYP2D6 phenotype in the metabolism of propafenone (Pro) enantiomers in 16 HAN Chinese subjects. METHODS: Seven very extensive metabolizers (VEM) and nine intermediate metabolizers (IM) were enrolled from a Chinese population whose phenotype had been previously assessed with a dextromethorphan metabolic phenotyping. The blood samples (0-15 h) were taken after oral administration...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents
Share to Asian People
Share to China

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Phenotype

Share to Stereoisomerism

Source

Identifiers

PMID: 10678105

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects.PMID 10678105Read ↗

Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers.Semantic proximity Read ↗

Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects.Semantic proximity Read ↗

Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects.Semantic proximity Read ↗

Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.Semantic proximity Read ↗

Assessment of 25 CYP2D6 alleles found in the Chinese population on propafenone metabolism in vitro.Semantic proximity Read ↗

Identification and drug metabolic activity evaluation of 12 CYP2D6 allelic variants newly detected in the Chinese population.Semantic proximity Read ↗

Use of a propafenone metabolic ratio as a measure of CYP2D6 activity.Semantic proximity Read ↗

Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10.Semantic proximity Read ↗

Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.Semantic proximity Read ↗

Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.Semantic proximity Read ↗

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.Semantic proximity Read ↗

Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.